

Peter Coyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2787178/publications.pdf>

Version: 2024-02-01

30
papers

4,365
citations

331670

21
h-index

454955

30
g-index

67
all docs

67
docs citations

67
times ranked

3699
citing authors

#	ARTICLE	IF	CITATIONS
1	Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. <i>New England Journal of Medicine</i> , 2021, 385, e83.	27.0	675
2	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	27.0	368
3	Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1288-1290.	27.0	356
4	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. <i>Nature Medicine</i> , 2021, 27, 2136-2143.	30.7	346
5	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. <i>Nature Medicine</i> , 2021, 27, 1614-1621.	30.7	337
6	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816.	27.0	311
7	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. <i>Nature Communications</i> , 2022, 13, .	12.8	188
8	Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting. <i>Clinical Infectious Diseases</i> , 2021, 73, e1830-e1840.	5.8	154
9	SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. <i>EClinicalMedicine</i> , 2021, 35, 100861.	7.1	153
10	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1930.	7.4	140
11	Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. <i>Scientific Reports</i> , 2021, 11, 6233.	3.3	117
12	Resuming professional football (soccer) during the COVID-19 pandemic in a country with high infection rates: a prospective cohort study. <i>British Journal of Sports Medicine</i> , 2021, 55, 1092-1098.	6.7	77
13	Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. <i>Emerging Infectious Diseases</i> , 2021, 27, 1343-1352.	4.3	74
14	Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. <i>Journal of Global Health</i> , 2021, 11, 05005.	2.7	71
15	Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. <i>Journal of Travel Medicine</i> , 2021, 28, .	3.0	69
16	SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab221.	0.9	58
17	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	8.4	54
18	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	12.8	53

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. <i>Scientific Reports</i> , 2021, 11, 18182.	3.3	49
20	Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, e1188-e1191.	5.8	38
21	Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers. <i>PLoS ONE</i> , 2021, 16, e0258820.	2.5	37
22	Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections. <i>Journal of Travel Medicine</i> , 2022, 29, .	3.0	37
23	Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. <i>BMJ Innovations</i> , 2021, 7, 327-336.	1.7	27
24	Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. <i>Infection, Genetics and Evolution</i> , 2021, 88, 104684.	2.3	22
25	Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. <i>Scientific Reports</i> , 2021, 11, 11837.	3.3	14
26	SARS-CoV-2 infection in mortuary and cemetery workers. <i>International Journal of Infectious Diseases</i> , 2021, 105, 621-625.	3.3	11
27	Case Report: Prolonged Viral Shedding in Six COVID-19 Patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1472-1475.	1.4	10
28	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. <i>Journal of Global Health</i> , 2022, 12, 05004.	2.7	7
29	Reporting of RT-PCR cycle threshold (Ct) values during the first wave of COVID-19 in Qatar improved result interpretation in clinical and public health settings. <i>Journal of Medical Microbiology</i> , 2022, 71, .	1.8	7
30	Cardiac arrest secondary to Covid19 pneumonia post full vaccination. <i>American Journal of Emergency Medicine</i> , 2021, 49, 257-258.	1.6	3